Free radical production and their targeted action on biomolecules have roles in aging and age-related disorders such as Parkinson’s disease (PD). There is an age-associated increase in oxidative damage to the brain, and aging is considered a risk factor for PD. Dopaminergic neurons show linear fallout of 5–10% per decade with aging; however, the rate and intensity of neuronal loss in patients with PD is more marked than that of aging. Here, we enumerate the common link between aging and PD at the cellular level with special reference to oxidative damage caused by free radicals. Oxidative damage includes mitochondrial dysfunction, dopamine auto-oxidation, α-synuclein aggregation, glial cell activation, alterations in calcium signaling, and excess free iron. Moreover, neurons encounter more oxidative stress as a counteracting mechanism with advancing age does not function properly. Alterations in transcriptional activity of various pathways, including nuclear factor erythroid 2-related factor 2, glycogen synthase kinase 3β, mitogen activated protein kinase, nuclear factor kappa B, and reduced activity of superoxide dismutase, catalase and glutathione with aging might be correlated with the increased incidence of PD.
References
[1]
Brand, M.D.; Affourtit, C.; Esteves, T.C.; Green, K.; Lambert, A.J.; Miwa, S.; Pakay, J.L.; Parker, N. Mitochondrial superoxide: Production, biological effects, and activation of uncoupling proteins. Free Radic. Biol. Med 2004, 37, 755–767.
[2]
Turrens, J.F. Mitochondrial formation of reactive oxygen species. J. Physiol 2003, 552, 335–344.
[3]
Thannickal, V.J.; Fanburg, B.L. Reactive oxygen species in cell signaling. Am. J. Physiol. Lung. Cell. Mol. Physiol 2000, 279, L1005–L1028.
[4]
Forman, H.J.; Torres, M. Reactive oxygen species and cell signaling: Respiratory burst in macrophage signaling. Am. J. Respir. Crit. Care Med 2002, 166, S4–S8.
[5]
Rhee, S.G. Redox signaling: Hydrogen peroxide as intracellular messenger. Exp. Mol. Med 1999, 31, 53–59.
[6]
Bedard, K.; Krause, K.H. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiol. Rev 2007, 87, 245–313.
[7]
Kaul, N.; Forman, H.J. Reactive Oxygen Species in Physiology and Toxicology: From Lipid Peroxidation to Transcriptional Activation; Rhodes, C.R., Ed.; Taylor and Francis: New York, NY, USA, 2000; pp. 310–335.
[8]
Nordberg, J.; Arner, E.S. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic. Biol. Med 2001, 31, 1287–1312.
[9]
Valko, M.; Rhodes, C.J.; Moncol, J.; Izakovic, M.; Mazur, M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact 2006, 160, 1–40.
[10]
Finkel, T. Oxidant signals and oxidative stress. Curr. Opin. Cell Biol 2003, 15, 247–254.
[11]
Lindahl, T.; Nyberg, B. Rate of depurination of native deoxyribonucleic acid. Biochemistry 1972, 11, 3610–3618.
[12]
Lindahl, T.; Karlstrom, O. Heat-induced depyrimidination of deoxyribonucleic acid in neutral solution. Biochemistry 1973, 12, 5151–5154.
[13]
Devasagayam, T.P.; Steenken, S.; Obendorf, M.S.; Schulz, W.A.; Sies, H. Formation of 8-hydroxy(deoxy)guanosine and generation of strand breaks at guanine residues in DNA by singlet oxygen. Biochemistry 1991, 30, 6283–6289.
[14]
Harman, D. Aging: A theory based on free radical and radiation chemistry. J. Gerontol 1956, 11, 298–300.
[15]
Harman, D. The biologic clock: The mitochondria? J. Am. Geriatr. Soc 1972, 20, 145–147.
[16]
Dei, R.; Takeda, A.; Niwa, H.; Li, M.; Nakagomi, Y.; Watanabe, M.; Inagaki, T.; Washimi, Y.; Yasuda, Y.; Horie, K.; et al. Lipid peroxidation and advanced glycation end products in the brain in normal aging and in Alzheimer’s disease. Acta Neuropathol 2002, 104, 113–122.
Starke-Reed, P.E.; Oliver, C.N. Protein oxidation and proteolysis during aging and oxidative stress. Arch. Biochem. Biophys 1989, 275, 559–567.
[19]
Parkes, T.L.; Elia, A.J.; Dickinson, D.; Hilliker, A.J.; Phillips, J.P.; Boulianne, G.L. Extension of Drosophila lifespan by overexpression of human SOD1 in motorneurons. Nat. Genet 1998, 19, 171–174.
[20]
Magwere, T.; West, M.; Riyahi, K.; Murphy, M.P.; Smith, R.A.; Partridge, L. The effects of exogenous antioxidants on lifespan and oxidative stress resistance in Drosophila melanogaster. Mech. Ageing Dev 2006, 127, 356–370.
[21]
Sohal, R.S. Role of oxidative stress and protein oxidation in the aging process. Free Radic. Biol. Med 2002, 33, 37–44.
[22]
Muller, F.L.; Lustgarten, M.S.; Jang, Y.; Richardson, A.; van Remmen, H. Trends in oxidative aging theories. Free Radic. Biol. Med 2007, 43, 477–503.
[23]
Przedborski, S.; Ischiropoulos, H. Reactive oxygen and nitrogen species: Weapons of neuronal destruction in models of Parkinson’s disease. Antioxid. Redox Signal 2005, 7, 685–693.
Alam, Z.I.; Daniel, S.E.; Lees, A.J.; Marsden, D.C.; Jenner, P.; Halliwell, B. A generalised increase in protein carbonyls in the brain in Parkinson’s but not incidental Lewy body disease. J. Neurochem 1997, 69, 1326–1329.
[26]
Dexter, D.; Carter, C.; Agid, F.; Agid, Y.; Lees, A.J.; Jenner, P.; Marsden, C.D. Lipid peroxidation as cause of nigral cell death in Parkinson’s disease. Lancet 1986, 2, 639–640.
[27]
Hamilton, M.L.; van Remmen, H.; Drake, J.A.; Yang, H.; Guo, Z.M.; Kewitt, K.; Walter, C.A.; Richardson, A. Does oxidative damage to DNA increase with age? Proc. Natl. Acad. Sci. USA 2001, 98, 10469–10474.
Morens, D.M.; Davis, J.W.; Grandinetti, A.; Ross, G.W.; Popper, J.S.; White, L.R. Epidemiologic observations on Parkinson’s disease: Incidence and mortality in a prospective study of middle-aged men. Neurology 1996, 46, 1044–1050.
[31]
De Lau, L.M.; Giesbergen, P.C.; de Rijk, M.C.; Hofman, A.; Koudstaal, P.J.; Breteler, M.M. Incidence of parkinsonism and Parkinson disease in a general population: The Rotterdam Study. Neurology 2004, 63, 1240–1244.
[32]
De Rijk, M.C.; Tzourio, C.; Breteler, M.M.; Dartigues, J.F.; Amaducci, L.; Lopez-Pousa, S.; Manubens-Bertran, J.M.; Alperovitch, A.; Rocca, W.A. Prevalence of parkinsonism and Parkinson’s disease in Europe: The Europarkinson collaborative study. European Community Concerted Action on the Epidemiology of Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 1997, 62, 10–15.
[33]
Fearnley, J.M.; Lees, A.J. Ageing and Parkinson’s disease: Substantia nigra regional selectivity. Brain 1991, 114, 2283–2301.
[34]
Mann, D.M.; Yates, P.O. Possible role of neuromelanin in the pathogenesis of Parkinson’s disease. Mech. Ageing Dev 1983, 21, 193–203.
[35]
Dorsey, E.R.; Constantinescu, R.; Thompson, J.P.; Biglan, K.M.; Holloway, R.G.; Kieburtz, K.; Marshall, F.J.; Ravina, B.M.; Schifitto, G.; Siderowf, A.; et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68, 384–386.
Beal, M.F. Therapeutic approaches to mitochondrial dysfunction in Parkinson’s disease. Parkinsonism Relat. Disord 2009, 15, S189–S194.
[38]
Kushnareva, Y.; Murphy, A.N.; Andreyev, A. Complex I-mediated reactive oxygen species generation: Modulation by cytochrome c and NAD(P)+ oxidation-reduction state. Biochem. J 2002, 368, 545–553.
[39]
Fasano, M.; Bergamasco, B.; Lopiano, L. Modifications of the iron-neuromelanin system in Parkinson’s disease. J. Neurochem 2006, 96, 909–916.
[40]
Ischiropoulos, H.; Beckman, J.S. Oxidative stress and nitration in neurodegeneration: Cause, effect, or association? J. Clin. Invest 2003, 111, 163–169.
[41]
Linnane, A.W.; Marzuki, S.; Ozawa, T.; Tanaka, M. Mitochondrial DNA mutations as an important contributor to ageing and degenerative diseases. Lancet 1989, 1, 642–645.
[42]
Kraytsberg, Y.; Kudryavtseva, E.; McKee, A.C.; Geula, C.; Kowall, N.W.; Khrapko, K. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat. Genet 2006, 38, 518–520.
[43]
Bender, A.; Krishnan, K.J.; Morris, C.M.; Taylor, G.A.; Reeve, A.K.; Perry, R.H.; Jaros, E.; Hersheson, J.S.; Betts, J.; Klopstock, T.; et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet 2006, 38, 515–517.
[44]
Anderson, S.; Bankier, A.T.; Barrell, B.G.; de Bruijn, M.H.; Coulson, A.R.; Drouin, J.; Eperon, I.C.; Nierlich, D.P.; Roe, B.A.; Sanger, F.; et al. Sequence and organization of the human mitochondrial genome. Nature 1981, 290, 457–465.
[45]
Pinton, P.; Rimessi, A.; Marchi, S.; Orsini, F.; Migliaccio, E.; Giorgio, M.; Contursi, C.; Minucci, S.; Mantovani, F.; Wieckowski, M.R.; et al. Protein kinase C beta and prolyl isomerase 1 regulate mitochondrial effects of the life-span determinant p66Shc. Science 2007, 315, 659–663.
[46]
Ruan, H.; Tang, X.D.; Chen, M.L.; Joiner, M.L.; Sun, G.; Brot, N.; Weissbach, H.; Heinemann, S.H.; Iverson, L.; Wu, C.F.; et al. High-quality life extension by the enzyme peptide methionine sulfoxide reductase. Proc. Natl. Acad. Sci. USA 2002, 99, 2748–2753.
[47]
Kujoth, G.C.; Hiona, A.; Pugh, T.D.; Someya, S.; Panzer, K.; Wohlgemuth, S.E.; Hofer, T.; Seo, A.Y.; Sullivan, R.; Jobling, W.A.; et al. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 2005, 309, 481–484.
[48]
Trifunovic, A.; Wredenberg, A.; Falkenberg, M.; Spelbrink, J.N.; Rovio, A.T.; Bruder, C.E.; Bohlooly, Y.M.; Gidlof, S.; Oldfors, A.; Wibom, R.; et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004, 429, 417–423.
[49]
Davidzon, G.; Greene, P.; Mancuso, M.; Klos, K.J.; Ahlskog, J.E.; Hirano, M.; DiMauro, S. Early-onset familial parkinsonism due to POLG mutations. Ann. Neurol 2006, 59, 859–862.
[50]
Ahluwalia, N.; Gordon, M.A.; Handte, G.; Mahlon, M.; Li, N.Q.; Beard, J.L.; Weinstock, D.; Ross, A.C. Iron status and stores decline with age in Lewis rats. J. Nutr 2000, 130, 2378–2383.
[51]
Bonifati, V.; Rizzu, P.; van Baren, M.J.; Schaap, O.; Breedveld, G.J.; Krieger, E.; Dekker, M.C.; Squitieri, F.; Ibanez, P.; Joosse, M.; et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003, 299, 256–259.
[52]
Van Duijn, C.M.; Dekker, M.C.; Bonifati, V.; Galjaard, R.J.; Houwing-Duistermaat, J.J.; Snijders, P.J.; Testers, L.; Breedveld, G.J.; Horstink, M.; Sandkuijl, L.A.; et al. Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am. J. Hum. Genet 2001, 69, 629–634.
[53]
Lesage, S.; Brice, A. Role of Mendelian genes in “sporadic” Parkinson’s disease. Parkinsonism Relat. Disord 2012, 18, S66–S70.
[54]
Horowitz, M.P.; Greenamyre, J.T. Gene-environment interactions in Parkinson’s disease: The importance of animal modeling. Clin. Pharmacol. Ther 2010, 88, 467–474.
[55]
Meulener, M.C.; Xu, K.; Thomson, L.; Ischiropoulos, H.; Bonini, N.M. Mutational analysis of DJ-1 in Drosophila implicates functional inactivation by oxidative damage and aging. Proc. Natl. Acad. Sci. USA 2006, 103, 12517–12522.
[56]
Yamaguchi, H.; Shen, J. Absence of dopaminergic neuronal degeneration and oxidative damage in aged DJ-1-deficient mice. Mol. Neurodegener 2007, 2, doi:10.1186/1750-1326-2-10.
[57]
Kawajiri, S.; Saiki, S.; Sato, S.; Hattori, N. Genetic mutations and functions of PINK1. Trends Pharmacol. Sci 2011, 32, 573–580.
Todd, A.M.; Staveley, B.E. Pink1 suppresses alpha-synuclein-induced phenotypes in a Drosophila model of Parkinson’s disease. Genome 2008, 51, 1040–1046.
[60]
Haywood, A.F.; Staveley, B.E. Parkin counteracts symptoms in a Drosophila model of Parkinson’s disease. BMC Neurosci 2004, 5, doi:10.1186/1471-2202-5-14.
[61]
Palacino, J.J.; Sagi, D.; Goldberg, M.S.; Krauss, S.; Motz, C.; Wacker, M.; Klose, J.; Shen, J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem 2004, 279, 18614–18622.
[62]
Perez, F.A.; Palmiter, R.D. Parkin-deficient mice are not a robust model of parkinsonism. Proc. Natl. Acad. Sci. USA 2005, 102, 2174–2179.
[63]
Periquet, M.; Corti, O.; Jacquier, S.; Brice, A. Proteomic analysis of parkin knockout mice: Alterations in energy metabolism, protein handling and synaptic function. J. Neurochem 2005, 95, 1259–1276.
[64]
Kitada, T.; Asakawa, S.; Hattori, N.; Matsumine, H.; Yamamura, Y.; Minoshima, S.; Yokochi, M.; Mizuno, Y.; Shimizu, N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392, 605–608.
[65]
Hedrich, K.; Eskelson, C.; Wilmot, B.; Marder, K.; Harris, J.; Garrels, J.; Meija-Santana, H.; Vieregge, P.; Jacobs, H.; Bressman, S.B.; et al. Distribution, type, and origin of Parkin mutations: Review and case studies. Mov. Disord 2004, 19, 1146–1157.
[66]
Lucking, C.B.; Durr, A.; Bonifati, V.; Vaughan, J.; de Michele, G.; Gasser, T.; Harhangi, B.S.; Meco, G.; Denefle, P.; Wood, N.W.; et al. Association between early-onset Parkinson’s disease and mutations in the parkin gene. N. Engl. J. Med 2000, 342, 1560–1567.
[67]
Periquet, M.; Latouche, M.; Lohmann, E.; Rawal, N.; de Michele, G.; Ricard, S.; Teive, H.; Fraix, V.; Vidailhet, M.; Nicholl, D.; et al. Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain 2003, 126, 1271–1278.
[68]
Lohmann, E.; Periquet, M.; Bonifati, V.; Wood, N.W.; de Michele, G.; Bonnet, A.M.; Fraix, V.; Broussolle, E.; Horstink, M.W.; Vidailhet, M.; et al. How much phenotypic variation can be attributed to parkin genotype? Ann. Neurol 2003, 54, 176–185.
[69]
Foroud, T.; Uniacke, S.K.; Liu, L.; Pankratz, N.; Rudolph, A.; Halter, C.; Shults, C.; Marder, K.; Conneally, P.M.; Nichols, W.C. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology 2003, 60, 796–801.
[70]
Sun, M.; Latourelle, J.C.; Wooten, G.F.; Lew, M.F.; Klein, C.; Shill, H.A.; Golbe, L.I.; Mark, M.H.; Racette, B.A.; Perlmutter, J.S.; et al. Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: The GenePD study. Arch. Neurol 2006, 63, 826–832.
[71]
Broussolle, E.; Lucking, C.B.; Ginovart, N.; Pollak, P.; Remy, P.; Durr, A. [18 F]-dopa PET study in patients with juvenile-onset PD and parkin gene mutations. Neurology 2000, 55, 877–879.
[72]
Shulman, J.M.; de Jager, P.L.; Feany, M.B. Parkinson’s disease: Genetics and pathogenesis. Annu. Rev. Pathol 2011, 6, 193–222.
[73]
Slivka, A.; Cohen, G. Hydroxyl radical attack on dopamine. J. Biol. Chem 1985, 260, 15466–15472.
[74]
Fornstedt, B.; Pileblad, E.; Carlsson, A. In vivo autoxidation of dopamine in guinea pig striatum increases with age. J. Neurochem 1990, 55, 655–659.
[75]
Sulzer, D.; Zecca, L. Intraneuronal dopamine-quinone synthesis: A review. Neurotox. Res 2000, 1, 181–195.
[76]
Mann, J.J.; Stanley, M. Postmortem monoamine oxidase enzyme kinetics in the frontal cortex of suicide victims and controls. Acta Psychiatr. Scand 1984, 69, 135–139.
[77]
Jossan, S.S.; Gillberg, P.G.; d’Argy, R.; Aquilonius, S.M.; Langstrom, B.; Halldin, C.; Oreland, L. Quantitative localization of human brain monoamine oxidase B by large section autoradiography using l-[3H]deprenyl. Brain Res 1991, 547, 69–76.
[78]
Strolin Benedetti, M.; Dostert, P. Monoamine oxidase, brain ageing and degenerative diseases. Biochem. Pharmacol 1989, 38, 555–561.
Morgan, D.G.; May, P.C.; Finch, C.E. Dopamine and serotonin systems in human and rodent brain: Effects of age and neurodegenerative disease. J. Am. Geriatr. Soc 1987, 35, 334–345.
[81]
Kish, S.J.; Shannak, K.; Rajput, A.; Deck, J.H.; Hornykiewicz, O. Aging produces a specific pattern of striatal dopamine loss: Implications for the etiology of idiopathic Parkinson’s disease. J. Neurochem 1992, 58, 642–648.
[82]
Thannickal, T.C.; Lai, Y.Y.; Siegel, J.M. Hypocretin (orexin) and melanin concentrating hormone loss and the symptoms of Parkinson’s disease. Brain 2008, 131, e87.
[83]
Cruz-Muros, I.; Afonso-Oramas, D.; Abreu, P.; Barroso-Chinea, P.; Rodriguez, M.; Gonzalez, M.C.; Hernandez, T.G. Aging of the rat mesostriatal system: Differences between the nigrostriatal and the mesolimbic compartments. Exp. Neurol 2007, 204, 147–161.
[84]
Goudsmit, E.; Feenstra, M.G.; Swaab, D.F. Central monoamine metabolism in the male Brown-Norway rat in relation to aging and testosterone. Brain Res. Bull 1990, 25, 755–763.
[85]
Volkow, N.D.; Ding, Y.S.; Fowler, J.S.; Wang, G.J.; Logan, J.; Gatley, S.J.; Hitzemann, R.; Smith, G.; Fields, S.D.; Gur, R. Dopamine transporters decrease with age. J. Nucl. Med 1996, 37, 554–559.
Gonzalez-Hernandez, T.; Barroso-Chinea, P.; de La Cruz Muros, I.; del Mar Perez-Delgado, M.; Rodriguez, M. Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons. J. Comp. Neurol 2004, 479, 198–215.
[88]
Cantuti-Castelvetri, I.; Shukitt-Hale, B.; Joseph, J.A. Dopamine neurotoxicity: Age-dependent behavioral and histological effects. Neurobiol. Aging 2003, 24, 697–706.
[89]
De Keyser, J.; Ebinger, G.; Vauquelin, G. Age-related changes in the human nigrostriatal dopaminergic system. Ann. Neurol 1990, 27, 157–161.
[90]
Irwin, I.; DeLanney, L.E.; McNeill, T.; Chan, P.; Forno, L.S.; Murphy, G.M., Jr; di Monte, D.A.; Sandy, M.S.; Langston, J.W. Aging and the nigrostriatal dopamine system: A non-human primate study. Neurodegeneration 1994, 3, 251–265.
[91]
Borges, C.R.; Geddes, T.; Watson, J.T.; Kuhn, D.M. Dopamine biosynthesis is regulated by S-glutathionylation. Potential mechanism of tyrosine hydroxylast inhibition during oxidative stress. J. Biol. Chem 2002, 277, 48295–48302.
[92]
De La Cruz, C.P.; Revilla, E.; Venero, J.L.; Ayala, A.; Cano, J.; Machado, A. Oxidative inactivation of tyrosine hydroxylase in substantia nigra of aged rat. Free Radic. Biol. Med 1996, 20, 53–61.
[93]
Ischiropoulos, H. Biological tyrosine nitration: A pathophysiological function of nitric oxide and reactive oxygen species. Arch. Biochem. Biophys 1998, 356, 1–11.
[94]
Goedert, M. Familial Parkinson’s disease. The awakening of alpha-synuclein. Nature 1997, 388, 232–233.
[95]
Yu, S.; Ueda, K.; Chan, P. Alpha-synuclein and dopamine metabolism. Mol. Neurobiol 2005, 31, 243–254.
[96]
Perez, R.G.; Hastings, T.G. Could a loss of alpha-synuclein function put dopaminergic neurons at risk? J. Neurochem 2004, 89, 1318–1324.
[97]
Kim, K.S.; Choi, S.Y.; Kwon, H.Y.; Won, M.H.; Kang, T.C.; Kang, J.H. Aggregation of alpha-synuclein induced by the Cu,Zn-superoxide dismutase and hydrogen peroxide system. Free Radic. Biol. Med 2002, 32, 544–550.
[98]
Conway, K.A.; Rochet, J.C.; Bieganski, R.M.; Lansbury, P.T., Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001, 294, 1346–1349.
[99]
Xu, J.; Kao, S.Y.; Lee, F.J.; Song, W.; Jin, L.W.; Yankner, B.A. Dopamine-dependent neurotoxicity of alpha-synuclein: A mechanism for selective neurodegeneration in Parkinson disease. Nat. Med 2002, 8, 600–606.
[100]
Borghi, R.; Marchese, R.; Negro, A.; Marinelli, L.; Forloni, G.; Zaccheo, D.; Abbruzzese, G.; Tabaton, M. Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson’s disease and normal subjects. Neurosci. Lett 2000, 287, 65–67.
[101]
Chu, Y.; Kordower, J.H. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson’s disease? Neurobiol. Dis 2007, 25, 134–149.
[102]
Jellinger, K.A. Lewy body-related alpha-synucleinopathy in the aged human brain. J. Neural. Transm 2004, 111, 1219–1235.
[103]
Li, W.; Lesuisse, C.; Xu, Y.; Troncoso, J.C.; Price, D.L.; Lee, M.K. Stabilization of alpha-synuclein protein with aging and familial parkinson’s disease-linked A53T mutation. J. Neurosci 2004, 24, 7400–7409.
[104]
Buchman, A.S.; Shulman, J.M.; Nag, S.; Leurgans, S.E.; Arnold, S.E.; Morris, M.C.; Schneider, J.A.; Bennett, D.A. Nigral pathology and parkinsonian signs in elders without Parkinson disease. Ann. Neurol 2012, 71, 258–266.
[105]
Adamczyk, A.; Kazmierczak, A.; Strosznajder, J.B. Alpha-synuclein and its neurotoxic fragment inhibit dopamine uptake into rat striatal synaptosomes. Relationship to nitric oxide. Neurochem. Int 2006, 49, 407–412.
[106]
Saito, Y.; Kawashima, A.; Ruberu, N.N.; Fujiwara, H.; Koyama, S.; Sawabe, M.; Arai, T.; Nagura, H.; Yamanouchi, H.; Hasegawa, M.; et al. Accumulation of phosphorylated alpha-synuclein in aging human brain. J. Neuropathol. Exp. Neurol 2003, 62, 644–654.
[107]
Junn, E.; Mouradian, M.M. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci. Lett 2002, 320, 146–150.
[108]
Hashimoto, M.; Hsu, L.J.; Xia, Y.; Takeda, A.; Sisk, A.; Sundsmo, M.; Masliah, E. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 1999, 10, 717–721.
[109]
Turnbull, S.; Tabner, B.J.; El-Agnaf, O.M.; Moore, S.; Davies, Y.; Allsop, D. Alpha-Synuclein implicated in Parkinson’s disease catalyses the formation of hydrogen peroxide in vitro. Free Radic. Biol. Med 2001, 30, 1163–1170.
[110]
Hartl, F.U. Molecular chaperones in cellular protein folding. Nature 1996, 381, 571–579.
[111]
Neumann, M.; Kahle, P.J.; Giasson, B.I.; Ozmen, L.; Borroni, E.; Spooren, W.; Muller, V.; Odoy, S.; Fujiwara, H.; Hasegawa, M.; et al. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J. Clin. Invest 2002, 110, 1429–1439.
[112]
Beach, T.G.; Walker, D.G.; Sue, L.I.; Newell, A.; Adler, C.C.; Joyce, J.N. Substantia nigra Marinesco bodies are associated with decreased striatal expression of dopaminergic markers. J. Neuropathol. Exp. Neurol 2004, 63, 329–337.
[113]
Braak, H.; del Tredici, K.; Rub, U.; de Vos, R.A.; Jansen Steur, E.N.; Braak, E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 2003, 24, 197–211.
[114]
Cuervo, A.M.; Stefanis, L.; Fredenburg, R.; Lansbury, P.T.; Sulzer, D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004, 305, 1292–1295.
[115]
Lee, H.J.; Khoshaghideh, F.; Patel, S.; Lee, S.J. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J. Neurosci 2004, 24, 1888–1896.
[116]
Webb, J.L.; Ravikumar, B.; Atkins, J.; Skepper, J.N.; Rubinsztein, D.C. Alpha-Synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem 2003, 278, 25009–25013.
[117]
Perry, V.H.; Nicoll, J.A.; Holmes, C. Microglia in neurodegenerative disease. Nat. Rev. Neurol 2010, 6, 193–201.
[118]
Xu, H.; Chen, M.; Forrester, J.V. Para-inflammation in the aging retina. Prog. Retin. Eye Res 2009, 28, 348–368.
[119]
Price, N.E.; Wadzinski, B.; Mumby, M.C. An anchoring factor targets protein phosphatase 2A to brain microtubules. Brain Res. Mol. Brain Res 1999, 73, 68–77.
[120]
Klegeris, A.; McGeer, E.G.; McGeer, P.L. Therapeutic approaches to inflammation in neurodegenerative disease. Curr. Opin. Neurol 2007, 20, 351–357.
[121]
Beach, T.G.; Sue, L.I.; Walker, D.G.; Lue, L.F.; Connor, D.J.; Caviness, J.N.; Sabbagh, M.N.; Adler, C.H. Marked microglial reaction in normal aging human substantia nigra: Correlation with extraneuronal neuromelanin pigment deposits. Acta Neuropathol 2007, 114, 419–424.
[122]
Roy, A.; Jana, A.; Yatish, K.; Freidt, M.B.; Fung, Y.K.; Martinson, J.A.; Pahan, K. Reactive oxygen species up-regulate CD11b in microglia via nitric oxide: Implications for neurodegenerative diseases. Free Radic. Biol. Med 2008, 45, 686–699.
[123]
McGeer, P.L.; Itagaki, S.; Boyes, B.E.; McGeer, E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 1988, 38, 1285–1291.
[124]
Imamura, K.; Hishikawa, N.; Sawada, M.; Nagatsu, T.; Yoshida, M.; Hashizume, Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains. Acta Neuropathol 2003, 106, 518–526.
[125]
Gerhard, A.; Pavese, N.; Hotton, G.; Turkheimer, F.; Es, M.; Hammers, A.; Eggert, K.; Oertel, W.; Banati, R.B.; Brooks, D.J. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol. Dis 2006, 21, 404–412.
[126]
Aloisi, F. Cytokine Production. In Neuroglia; Kettenmann, H., Ransom, B.R., Eds.; Oxford University Press: New York, NY, USA, 2005; pp. 285–301.
[127]
Sierra, A.; Gottfried-Blackmore, A.C.; McEwen, B.S.; Bulloch, K. Microglia derived from aging mice exhibit an altered inflammatory profile. Glia 2007, 55, 412–424.
[128]
Sawada, M.; Sawada, H.; Nagatsu, T. Effects of aging on neuroprotective and neurotoxic properties of microglia in neurodegenerative diseases. Neurodegener. Dis 2008, 5, 254–256.
[129]
Godbout, J.P.; Chen, J.; Abraham, J.; Richwine, A.F.; Berg, B.M.; Kelley, K.W.; Johnson, R.W. Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. FASEB J 2005, 19, 1329–1331.
[130]
Damani, M.R.; Zhao, L.; Fontainhas, A.M.; Amaral, J.; Fariss, R.N.; Wong, W.T. Age-related alterations in the dynamic behavior of microglia. Aging Cell 2011, 10, 263–276.
[131]
Gregory, A.; Polster, B.J.; Hayflick, S.J. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J. Med. Genet 2009, 46, 73–80.
[132]
Colton, C.A.; Gilbert, D.L. Production of superoxide anions by a CNS macrophage, the microglia. FEBS Lett 1987, 223, 284–288.
[133]
Biemond, P.; van Eijk, H.G.; Swaak, A.J.; Koster, J.F. Iron mobilization from ferritin by superoxide derived from stimulated polymorphonuclear leukocytes. Possible mechanism in inflammation diseases. J. Clin. Invest 1984, 73, 1576–1579.
[134]
Agrawal, R.; Sharma, P.K.; Rao, G.S. Release of iron from ferritin by metabolites of benzene and superoxide radical generating agents. Toxicology 2001, 168, 223–230.
[135]
Tanaka, M.; Sotomatsu, A.; Yoshida, T.; Hirai, S.; Nishida, A. Detection of superoxide production by activated microglia using a sensitive and specific chemiluminescence assay and microglia-mediated PC12h cell death. J. Neurochem 1994, 63, 266–270.
[136]
Chen, Y.; Swanson, R.A. Astrocytes and brain injury. J. Cereb. Blood Flow Metab 2003, 23, 137–149.
[137]
Nichols, N.R. Glial responses to steroids as markers of brain aging. J. Neurobiol 1999, 40, 585–601.
[138]
Porchet, R.; Probst, A.; Bouras, C.; Draberova, E.; Draber, P.; Riederer, B.M. Analysis of glial acidic fibrillary protein in the human entorhinal cortex during aging and in Alzheimer’s disease. Proteomics 2003, 3, 1476–1485.
[139]
Peinado, M.A.; Quesada, A.; Pedrosa, J.A.; Torres, M.I.; Martinez, M.; Esteban, F.J.; del Moral, M.L.; Hernandez, R.; Rodrigo, J.; Peinado, J.M. Quantitative and ultrastructural changes in glia and pericytes in the parietal cortex of the aging rat. Microsc. Res. Tech 1998, 43, 34–42.
[140]
Pilegaard, K.; Ladefoged, O. Total number of astrocytes in the molecular layer of the dentate gyrus of rats at different ages. Anal. Quant. Cytol. Histol 1996, 18, 279–285.
[141]
Rozovsky, I.; Finch, C.E.; Morgan, T.E. Age-related activation of microglia and astrocytes: In vitro studies show persistent phenotypes of aging, increased proliferation, and resistance to down-regulation. Neurobiol. Aging 1998, 19, 97–103.
[142]
Ballatori, N.; Krance, S.M.; Notenboom, S.; Shi, S.; Tieu, K.; Hammond, C.L. Glutathione dysregulation and the etiology and progression of human diseases. Biol. Chem 2009, 390, 191–214.
[143]
Rice, M.E.; Russo-Menna, I. Differential compartmentalization of brain ascorbate and glutathione between neurons and glia. Neuroscience 1998, 82, 1213–1223.
[144]
Gegg, M.E.; Beltran, B.; Salas-Pino, S.; Bolanos, J.P.; Clark, J.B.; Moncada, S.; Heales, S.J. Differential effect of nitric oxide on glutathione metabolism and mitochondrial function in astrocytes and neurones: Implications for neuroprotection/neurodegeneration? J. Neurochem 2003, 86, 228–237.
[145]
Sian, J.; Dexter, D.T.; Lees, A.J.; Daniel, S.; Agid, Y.; Javoy-Agid, F.; Jenner, P.; Marsden, C.D. Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol 1994, 36, 348–355.
[146]
O’Callaghan, J.P.; Miller, D.B. The concentration of glial fibrillary acidic protein increases with age in the mouse and rat brain. Neurobiol. Aging 1991, 12, 171–174.
[147]
Uchida, K.; Kihara, N.; Hashimoto, K.; Nakayama, H.; Yamaguchi, R.; Tateyama, S. Age-related histological changes in the canine substantia nigra. J. Vet. Med. Sci 2003, 65, 179–185.
[148]
Gu, X.L.; Long, C.X.; Sun, L.; Xie, C.; Lin, X.; Cai, H. Astrocytic expression of Parkinson’s disease-related A53T alpha-synuclein causes neurodegeneration in mice. Mol. Brain 2010, 3, doi:10.1186/1756-6606-3-12.
[149]
Giasson, B.I.; Duda, J.E.; Quinn, S.M.; Zhang, B.; Trojanowski, J.Q.; Lee, V.M. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002, 34, 521–533.
[150]
Lee, M.K.; Stirling, W.; Xu, Y.; Xu, X.; Qui, D.; Mandir, A.S.; Dawson, T.M.; Copeland, N.G.; Jenkins, N.A.; Price, D.L. Human alpha-synuclein-harboring familial Parkinson’s disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. USA 2002, 99, 8968–8973.
[151]
Park, S.J.; Lee, J.H.; Kim, H.Y.; Choi, Y.H.; Park, J.S.; Suh, Y.H.; Park, S.M.; Joe, E.H.; Jou, I. Astrocytes, but not microglia, rapidly sense H2O2 via STAT6 phosphorylation, resulting in cyclooxygenase-2 expression and prostaglandin release. J. Immunol 2012, 188, 5132–5141.
[152]
Khachaturian, Z.S. The role of calcium regulation in brain aging: Reexamination of a hypothesis. Aging (Milano) 1989, 1, 17–34.
[153]
Bean, B.P. The action potential in mammalian central neurons. Nat. Rev. Neurosci 2007, 8, 451–465.
[154]
Bonci, A.; Grillner, P.; Mercuri, N.B.; Bernardi, G. L-Type calcium channels mediate a slow excitatory synaptic transmission in rat midbrain dopaminergic neurons. J. Neurosci 1998, 18, 6693–6703.
[155]
Puopolo, M.; Raviola, E.; Bean, B.P. Roles of subthreshold calcium current and sodium current in spontaneous firing of mouse midbrain dopamine neurons. J. Neurosci 2007, 27, 645–656.
Pignatelli, A.; Kobayashi, K.; Okano, H.; Belluzzi, O. Functional properties of dopaminergic neurones in the mouse olfactory bulb. J. Physiol 2005, 564, 501–514.
[158]
German, D.C.; Manaye, K.F.; Sonsalla, P.K.; Brooks, B.A. Midbrain dopaminergic cell loss in Parkinson’s disease and MPTP-induced parkinsonism: Sparing of calbindin-D28k-containing cells. Ann. N. Y. Acad. Sci 1992, 648, 42–62.
[159]
Belzunegui, S.; San Sebastian, W.; Garrido-Gil, P.; Izal-Azcarate, A.; Vazquez-Claverie, M.; Lopez, B.; Marcilla, I.; Lanciego, J.L.; Luquin, M.R. The number of dopaminergic cells is increased in the olfactory bulb of monkeys chronically exposed to MPTP. Synapse 2007, 61, 1006–1012.
[160]
Rizzuto, R.; Pozzan, T. Microdomains of intracellular Ca2+: Molecular determinants and functional consequences. Physiol. Rev 2006, 86, 369–408.
[161]
Verkhratsky, A. Physiology and pathophysiology of the calcium store in the endoplasmic reticulum of neurons. Physiol. Rev 2005, 85, 201–279.
[162]
Roveri, A.; Coassin, M.; Maiorino, M.; Zamburlini, A.; van Amsterdam, F.T.; Ratti, E.; Ursini, F. Effect of hydrogen peroxide on calcium homeostasis in smooth muscle cells. Arch. Biochem. Biophys 1992, 297, 265–270.
[163]
Wang, H.; Joseph, J.A. Mechanisms of hydrogen peroxide-induced calcium dysregulation in PC12 cells. Free Radic. Biol. Med 2000, 28, 1222–1231.
[164]
Thibault, O.; Landfield, P.W. Increase in single L-type calcium channels in hippocampal neurons during aging. Science 1996, 272, 1017–1020.
[165]
Altamura, S.; Muckenthaler, M.U. Iron toxicity in diseases of aging: Alzheimer’s disease, Parkinson’s disease and atherosclerosis. J. Alzheimers Dis 2009, 16, 879–895.
Dexter, D.T.; Sian, J.; Jenner, P.; Marsden, C.D. Implications of alterations in trace element levels in brain in Parkinson’s disease and other neurological disorders affecting the basal ganglia. Adv. Neurol 1993, 60, 273–281.
[168]
Connor, J.R.; Menzies, S.L.; St Martin, S.M.; Mufson, E.J. Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. J. Neurosci. Res 1990, 27, 595–611.
[169]
Roskams, A.J.; Connor, J.R. Iron, transferrin, and ferritin in the rat brain during development and aging. J. Neurochem 1994, 63, 709–716.
[170]
Bartzokis, G.; Tishler, T.A.; Lu, P.H.; Villablanca, P.; Altshuler, L.L.; Carter, M.; Huang, D.; Edwards, N.; Mintz, J. Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol. Aging 2007, 28, 414–423.
[171]
Berg, D.; Youdim, M.B.; Riederer, P. Redox imbalance. Cell Tissue Res 2004, 318, 201–213.
[172]
Seo, A.Y.; Xu, J.; Servais, S.; Hofer, T.; Marzetti, E.; Wohlgemuth, S.E.; Knutson, M.D.; Chung, H.Y.; Leeuwenburgh, C. Mitochondrial iron accumulation with age and functional consequences. Aging Cell 2008, 7, 706–716.
[173]
Aquino, D.; Bizzi, A.; Grisoli, M.; Garavaglia, B.; Bruzzone, M.G.; Nardocci, N.; Savoiardo, M.; Chiapparini, L. Age-related iron deposition in the basal ganglia: Quantitative analysis in healthy subjects. Radiology 2009, 252, 165–172.
[174]
Halliwell, B.; Gutteridge, J.M. Oxygen free radicals and iron in relation to biology and medicine: Some problems and concepts. Arch. Biochem. Biophys 1986, 246, 501–514.
[175]
Martin, W.R.; Ye, F.Q.; Allen, P.S. Increasing striatal iron content associated with normal aging. Mov. Disord 1998, 13, 281–286.
[176]
Zecca, L.; Stroppolo, A.; Gatti, A.; Tampellini, D.; Toscani, M.; Gallorini, M.; Giaveri, G.; Arosio, P.; Santambrogio, P.; Fariello, R.G.; et al. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc. Natl. Acad. Sci. USA 2004, 101, 9843–9848.
[177]
Leibold, E.A.; Gahring, L.C.; Rogers, S.W. Immunolocalization of iron regulatory protein expression in the murine central nervous system. Histochem. Cell Biol 2001, 115, 195–203.
[178]
Han, J.; Cheng, F.C.; Yang, Z.; Dryhurst, G. Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: Potential implications to Parkinson’s disease. J. Neurochem 1999, 73, 1683–1695.
[179]
Lan, J.; Jiang, D.H. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J. Neural. Transm 1997, 104, 469–481.
[180]
Shachar, D.B.; Kahana, N.; Kampel, V.; Warshawsky, A.; Youdim, M.B. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 2004, 46, 254–263.
[181]
Nguyen, T.; Sherratt, P.J.; Nioi, P.; Yang, C.S.; Pickett, C.B. Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap1. J. Biol. Chem 2005, 280, 32485–32492.
[182]
Moi, P.; Chan, K.; Asunis, I.; Cao, A.; Kan, Y.W. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc. Natl. Acad. Sci. USA 1994, 91, 9926–9930.
Von Otter, M.; Landgren, S.; Nilsson, S.; Celojevic, D.; Bergstrom, P.; Hakansson, A.; Nissbrandt, H.; Drozdzik, M.; Bialecka, M.; Kurzawski, M.; et al. Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson’s disease. BMC Med. Genet 2010, 11, doi:10.1186/1471-2350-11-36.
[185]
Suh, J.H.; Shenvi, S.V.; Dixon, B.M.; Liu, H.; Jaiswal, A.K.; Liu, R.M.; Hagen, T.M. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc. Natl. Acad. Sci. USA 2004, 101, 3381–3386.
[186]
Rojo, A.I.; Sagarra, M.R.; Cuadrado, A. GSK-3beta down-regulates the transcription factor Nrf2 after oxidant damage: Relevance to exposure of neuronal cells to oxidative stress. J. Neurochem 2008, 105, 192–202.
[187]
Ikeyama, S.; Kokkonen, G.; Shack, S.; Wang, X.T.; Holbrook, N.J. Loss in oxidative stress tolerance with aging linked to reduced extracellular signal-regulated kinase and Akt kinase activities. FASEB J 2002, 16, 114–116.
[188]
Kozikowski, A.P.; Gaisina, I.N.; Petukhov, P.A.; Sridhar, J.; King, L.T.; Blond, S.Y.; Duka, T.; Rusnak, M.; Sidhu, A. Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson’s disease. Chem. Med. Chem 2006, 1, 256–266.
Chen, C.; Pung, D.; Leong, V.; Hebbar, V.; Shen, G.; Nair, S.; Li, W.; Kong, A.N. Induction of detoxifying enzymes by garlic organosulfur compounds through transcription factor Nrf2: Effect of chemical structure and stress signals. Free Radic. Biol. Med 2004, 37, 1578–1590.
[191]
Silva, R.M.; Kuan, C.Y.; Rakic, P.; Burke, R.E. Mixed lineage kinase-c-jun N-terminal kinase signaling pathway: A new therapeutic target in Parkinson’s disease. Mov. Disord 2005, 20, 653–664.
[192]
Dagda, R.K.; Zhu, J.; Chu, C.T. Mitochondrial kinases in Parkinson’s disease: Converging insights from neurotoxin and genetic models. Mitochondrion 2009, 9, 289–298.
[193]
Shih, P.H.; Yen, G.C. Differential expressions of antioxidant status in aging rats: The role of transcriptional factor Nrf2 and MAPK signaling pathway. Biogerontology 2007, 8, 71–80.
[194]
Hsieh, C.C.; Rosenblatt, J.I.; Papaconstantinou, J. Age-associated changes in SAPK/JNK and p38 MAPK signaling in response to the generation of ROS by 3-nitropropionic acid. Mech. Ageing Dev 2003, 124, 733–746.
[195]
Hsieh, C.C.; Papaconstantinou, J. Dermal fibroblasts from long-lived Ames dwarf mice maintain their in vivo resistance to mitochondrial generated reactive oxygen species (ROS). Aging (Albany NY) 2009, 1, 784–802.
[196]
Helenius, M.; Hanninen, M.; Lehtinen, S.K.; Salminen, A. Changes associated with aging and replicative senescence in the regulation of transcription factor nuclear factor-kappa B. Biochem. J 1996, 318, 603–608.
[197]
Korhonen, P.; Helenius, M.; Salminen, A. Age-related changes in the regulation of transcription factor NF-kappa B in rat brain. Neurosci. Lett 1997, 225, 61–64.
[198]
Dehmer, T.; Lindenau, J.; Haid, S.; Dichgans, J.; Schulz, J.B. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J. Neurochem 2000, 74, 2213–2216.
[199]
Mogi, M.; Harada, M.; Kondo, T.; Riederer, P.; Inagaki, H.; Minami, M.; Nagatsu, T. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett 1994, 180, 147–150.
[200]
Sriram, K.; Matheson, J.M.; Benkovic, S.A.; Miller, D.B.; Luster, M.I.; O’Callaghan, J.P. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: Implications for Parkinson’s disease. FASEB J 2002, 16, 1474–1476.
[201]
Hayden, M.S.; Ghosh, S. Signaling to NF-kappaB. Genes Dev 2004, 18, 2195–2224.
[202]
Saggu, H.; Cooksey, J.; Dexter, D.; Wells, F.R.; Lees, A.; Jenner, P.; Marsden, C.D. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J. Neurochem 1989, 53, 692–697.
[203]
Tsay, H.J.; Wang, P.; Wang, S.L.; Ku, H.H. Age-associated changes of superoxide dismutase and catalase activities in the rat brain. J. Biomed. Sci 2000, 7, 466–474.
[204]
Pearce, R.K.; Owen, A.; Daniel, S.; Jenner, P.; Marsden, C.D. Alterations in the distribution of glutathione in the substantia nigra in Parkinson’s disease. J. Neural. Transm 1997, 104, 661–677.
[205]
Sofic, E.; Lange, K.W.; Jellinger, K.; Riederer, P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson’s disease. Neurosci. Lett 1992, 142, 128–130.
[206]
Huang, C.S.; Anderson, M.E.; Meister, A. Amino acid sequence and function of the light subunit of rat kidney gamma-glutamylcysteine synthetase. J. Biol. Chem 1993, 268, 20578–20583.
[207]
Huang, C.S.; Chang, L.S.; Anderson, M.E.; Meister, A. Catalytic and regulatory properties of the heavy subunit of rat kidney gamma-glutamylcysteine synthetase. J. Biol. Chem 1993, 268, 19675–19680.
[208]
Lu, S.C.; Huang, Z.Z.; Yang, H.; Tsukamoto, H. Effect of thioacetamide on the hepatic expression of gamma-glutamylcysteine synthetase subunits in the Rat. Toxicol. Appl. Pharmacol 1999, 159, 161–168.
[209]
Zhu, Y.; Carvey, P.M.; Ling, Z. Age-related changes in glutathione and glutathione-related enzymes in rat brain. Brain Res 2006, 1090, 35–44.
[210]
Vermulst, M.; Bielas, J.H.; Kujoth, G.C.; Ladiges, W.C.; Rabinovitch, P.S.; Prolla, T.A.; Loeb, L.A. Mitochondrial point mutations do not limit the natural lifespan of mice. Nat. Genet 2007, 39, 540–543.
[211]
Schriner, S.E.; Linford, N.J.; Martin, G.M.; Treuting, P.; Ogburn, C.E.; Emond, M.; Coskun, P.E.; Ladiges, W.; Wolf, N.; van Remmen, H.; et al. Extension of murine life span by overexpression of catalase targeted to mitochondria. Science 2005, 308, 1909–1911.
[212]
Perier, C.; Bove, J.; Dehay, B.; Jackson-Lewis, V.; Rabinovitch, P.S.; Przedborski, S.; Vila, M. Apoptosis-inducing factor deficiency sensitizes dopaminergic neurons to parkinsonian neurotoxins. Ann. Neurol 2010, 68, 184–192.
